Stimulation with SARS-CoV-2-specific peptides revealed that myeloma patients had an increased percentage of Tfh cells reacting to these peptides with the production of IFN and TNF compared to lymphoma patients (Figure 4B). This evidence concerns the gene IFNA1 and plasma cell myeloma.